↑ Grab this Headline Animator

Citra Anticoagulants Announces CE Mark Approval for LOXXIT Catheter...

Citra Anticoagulants, Inc. a leading, developer and worldwide distributor of citrate-based anticoagulants reported today that it has received CE Mark approval for LOXXIT Catheter Lock Solution. This regulatory achievement clears the way for Citra to market and distribute this product throughout the European Union and in other countries that recognize the CE Mark.

LOXXIT Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, 5 mL, is a sterile solution that prevents the coagulation of blood, eliminates the growth of microorganisms in any type of intravenous catheter, and prevents biofilm formation because it eliminates the growth of bacteria, yeast, and fungi in the catheter lumen. LOXXIT is a preventive-action product and was designed to prevent problems from occurring rather than treating problems that have occurred.

In September 2007, Citra signed an exclusive Marketing Services Agreement with H.A.C. Pharma which appoints H.A.C. Pharma as the sole representative to promote the marketing and sales activities of LOXXIT Catheter Lock Solution to distributors in Europe, the Middle East, and Africa.

For more information on LOXXIT Catheter Lock Solution, contact H.A.C. Pharma if you are located in Europe, the Middle East, or Africa, or contact Citra Anticoagulants, Inc. for the rest of the world.

About Citra Anticoagulants

Headquartered in Braintree, Massachusetts, 10 minutes outside of Boston, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more information about Citra and our products, visit our website at www.hacpharma.com.

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Citra | Catheter Lock | catheter lock solution |

---

4901 readers online...

, Local News